Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023 04 29; 401(10386):1427-1437.. View in PubMed
  • Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding. Expert Rev Hematol. 2023 03; 16(sup1):107-127.. View in PubMed
  • The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A. Blood Adv. 2023 02 28; 7(4):620-629.. View in PubMed
  • Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023 02 23; 388(8):706-718.. View in PubMed
  • The dosing conundrum of emicizumab: To waste product or not? Res Pract Thromb Haemost. 2023 Feb; 7(2):100087. Young G . . View in PubMed
  • Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 12 27; 6(24):6140-6150.. View in PubMed
  • Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children’s Hospital Acquired Thrombosis (CHAT) Consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12793.. View in PubMed
  • Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia. 2023 Jan; 29(1):100-105.. View in PubMed
  • Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: A report from the children’s hospital acquired thrombosis (CHAT) consortium. Thromb Res. 2022 12; 220:116-120.. View in PubMed
  • Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children’s Hospital-Acquired Thrombosis consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12810.. View in PubMed